Akero Therapeutics, Inc.
AKRO
Classifica tra le azioni
#3734
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Prezzo delle azioni
$54.65
Ultima sincronizzazione: 2025-12-09
Capitalizzazione di mercato
$4.50B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
1.50%
Paese
US
Scambia Akero Therapeutics, Inc. (AKRO)
Categoria
Healthcare
EPS per Akero Therapeutics, Inc. (AKRO)
EPS al September 2025 TTM: $-3.74
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Akero Therapeutics, Inc., l’EPS attuale della società (TTM) è $-3.74. Alla fine del 2023, la società aveva un EPS di $-2.89 un aumento rispetto a rispetto a quello del 2022, che era di $-2.87.
Storico EPS per Akero Therapeutics, Inc. da 2017 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-3.74 | -0.27% |
| 2024 | $-3.75 | 29.76% |
| 2023 | $-2.89 | 0.70% |
| 2022 | $-2.87 | -0.69% |
| 2021 | $-2.89 | 14.68% |
| 2020 | $-2.52 | -13.10% |
| 2019 | $-2.90 | -24.68% |
| 2018 | $-3.85 | 2,306.25% |
| 2017 | $-0.16 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -563.10% |
US
|
|
| $-7.98 | 113.37% |
US
|
|
| $-5.29 | 41.44% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -841.71% |
NL
|
